Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that the Israel Patent Office has approved the granting of a patent for its anti-Staphylococcus aureus phages and provides an update on the development schedule for these phages.
The patent obtained in Israel is the first patent granted for this family of phages and provides protection through to the end of 2038.
The Staphylococcus aureus program, a bacterium considered a high global priority by the WHO1, is the Company's flagship program. It includes, at this stage, three clinical trials expected to start in the coming months: PhagoDAIR for which Pherecydes Pharma is the sponsor as well as PhagOS and PhagoPied which are financed by Hospital Clinical Research Programs (PHRC) and whose sponsors will be the University Hospital Centres of Bordeaux and Nîmes. In parallel, Pherecydes Pharma plans to make these phages available under AAC early access programs. The AAC and PhagoDAIR applications are currently being reviewed and the Company expects to receive responses by early 2022 and the first quarter of 2022 respectively. The initiation of the PhagoDAIR study is therefore expected during the first quarter of 2022 and that of the PhagOS and PhagoPied studies before the end of the first half of 2022.
Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, said: "We are very pleased to be continuing to strengthen our intellectual property. Following the patents granted in numerous jurisdictions for our anti-Pseudomonas aeruginosa and anti-Escherichia Coli phages, this first patent for our anti-Staphylococcus aureus phages further enhances our arsenal of protection covering the phages we are currently developing. This approach is part of our continuous efforts to protect our investments in our winning phages and the aggressive stance we have adopted in the promising therapeutic field of precision phage therapy. This first step reaffirms the intellectual property strategy implemented by the Company over recent years and will support the development of these assets in the coming months. All this is also taking place in an environment where the demand for compassionate treatments continues to be strong with 38 patients treated as of November 15, 2021 (including 24 patients with Staphylococcus aureus infection), i.e. 15 new patients treated in the first eleven months of 2021
Pherecydes Pharma has an active portfolio of four patents, each covering multiple phages and their variants against the target bacteria: Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia Coli. While some patents are still pending, others have already been granted in major jurisdictions such as the United States, Europe, Japan, Australia, Hong Kong and Israel.
For more details on this news, launch the video by clicking on the image below:
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied in several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.
For more information, www.pherecydes-pharma.com
Disclaimer
This press release contains non-factual elements, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of the Company. They incorporate known and unknown risks and uncertainties that could result in significant differences in results, profitability and expected events. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, counsels and employees have not verified the accuracy of, and make no representations or warranties about, statistical information or forecast information contained within this news release and that originates or is derived from third party sources or industry publications; these statistical data and forecast information are only used in this press release for information purposes. Finally, this press release may be drafted in French and in English. In the event of differences between the two texts, the French version will prevail.
| _________________ |
1 https://www.who.int/fr/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211128005232/en/
Contacts:
Pherecydes Pharma
Philippe Rousseau
CFO
investors@pherecydes-pharma.com
NewCap
Dusan Oresansky
Investor Relations
pherecydes@newcap.eu
T.: +33 1 44 71 94 92
NewCap
Arthur Rouillé
Media Relations
pherecydes@newcap.eu
T.: +33 1 44 71 00 15
